{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:42Z","timestamp":1777420842660,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Background: Real-life data on single-tablet regimen (STR) dolutegravir\/abacavir\/lamivudine (DTG\/ABC\/3TC) is scarce, and concerns about DTG neuropsychiatric adverse events (NP-AEs) have recently arisen. Objective: To explore the effectiveness and safety, in particular NP-AEs, of DTG\/ABC\/3TC in a cohort of HIV-1 adult infected patients. Pill burden, adherence to this STR, and the impact of switching on costs were also evaluated. Methods: This was an observational, retrospective study. The study population included antiretroviral therapy (ART)-naive and treatment-experienced (TE) patients who started DTG\/ABC\/3TC between February 1, 2016, and October 31, 2016. Effectiveness and safety were analyzed at week 48 (W48) by intention-to-treat analysis. The Cox regression model was used to investigate predictors of DTG\/ABC\/3TC discontinuation. Results: A total of 253 patients were included (44 ART na\u00efve, 209 TE). At W48, the proportion of patients with virological suppression was 72.7% (95% CI = 58.4-87.0) in ART-naive patients, 85.6% (95% CI = 80.3-90.9) in previously suppressed TE patients, and 86.4% (95% CI = 65.1-97.1) in previously not suppressed TE patients. The rate of protocol-defined virological failure was 4.3%. The incidence of AEs was higher in the subgroup of ART-naive patients (56.1% vs 39.0%), with a rate of interruptions for this reason of 13.6% and 7.6%, respectively. The incidence of NP-AEs was 20.6%, with 3.9% of patients requiring discontinuation. Patients who had switched from a raltegravir-containing regimen discontinued DTG\/ABC\/3TC because of AEs more frequently (relative risk = 2.83; 95% CI = 1.04-7.72; P = 0.041) in the multivariate analysis. After switching to DTG\/ABC\/3TC, the median pill burden was reduced from 3 to 1 and the proportion of patients with an adherence &lt;90%, from 20.1% to 12.0%. The annual per-patient ART costs increased by \u20ac48 (0.6% increase). Conclusion and Relevance: DTG\/ABC\/3TC is an effective strategy as first-line and switching ART. Our data suggest a worse tolerance in ART-naive patients, although the rate of discontinuation resulting from NP-AEs was relatively low. In the short-term, the adherence was slightly improved without significant changes in costs.<\/jats:p>","DOI":"10.1177\/1060028019896638","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T03:35:38Z","timestamp":1578454538000},"page":"633-643","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness, Safety, and Costs of Dolutegravir\/Abacavir\/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients"],"prefix":"10.1177","volume":"54","author":[{"given":"Carmen Guadalupe","family":"Rodriguez-Gonzalez","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Chamorro-de-Vega","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ortega-Navarro","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Alonso","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Herranz-Alonso","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sanjurjo-Saez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"bibr1-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"bibr2-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"bibr3-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"bibr4-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"bibr5-1060028019896638","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3166"},{"key":"bibr6-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"bibr7-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001279"},{"key":"bibr8-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1177\/0956462416688127"},{"key":"bibr9-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12828"},{"key":"bibr10-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"bibr11-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"bibr12-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0322-8"},{"key":"bibr13-1060028019896638","unstructured":"Stanford University. HIV drug resistance database. http:\/\/hivdb.stanford.edu. Accessed October 15, 2018."},{"key":"bibr14-1060028019896638","unstructured":"US Department of Health and Human Services, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Published May 28, 2009. Accessed December 6, 2019."},{"key":"bibr15-1060028019896638","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3297"},{"key":"bibr16-1060028019896638","volume-title":"Paper presented at: Conference of HIV Drug Therapy Glasgow","author":"Wolf T"},{"key":"bibr17-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25227"},{"key":"bibr18-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"bibr19-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001357"},{"key":"bibr20-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12510"},{"key":"bibr21-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001459"},{"key":"bibr22-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001590"},{"key":"bibr23-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx053"},{"key":"bibr24-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001781"},{"key":"bibr25-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky497"},{"key":"bibr26-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001351"},{"key":"bibr27-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"key":"bibr28-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230"},{"key":"bibr29-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"bibr30-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz407"},{"key":"bibr31-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25324"},{"key":"bibr32-1060028019896638","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019896638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019896638","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019896638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:21Z","timestamp":1777374921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019896638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1177\/1060028019896638"],"URL":"https:\/\/doi.org\/10.1177\/1060028019896638","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]}}}